InventisBio will present the latest Phase II clinical trial data of Garsorasib (D-1553) in KRAS G12C-mutant non-small cell lung cancer (NSCLC) patients at the 2024 American Association for Cancer Research (AACR) Annual Meeting. This marks the second major international conference appearance for this study (NCT05383898), following its presentation at the 2022 World Lung Cancer Conference (WCLC).
The 2024 AACR Annual Meeting will be held from April 5-10, 2024, in San Diego, USA. We invite you to stay tuned for the exciting new findings!
Presentation Details:
- Abstract Number: CT246
- Abstract Type: Late-Breaking Abstract
- Abstract Title: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer
This presentation will highlight the most recent data from the ongoing Phase II study of Garsorasib in patients with KRAS G12C-mutant NSCLC, focusing on the efficacy and safety outcomes. This study is pivotal in assessing Garsorasib as a potential treatment for a patient population with limited therapeutic options, offering a promising new treatment avenue for those with this aggressive form of cancer.
Stay tuned for the full presentation at AACR 2024!